| Name | Title | Contact Details |
|---|
MANUFACTURING Philosophy The TRC team understands that the actions required to be a successful pharmaceutical manufacturer are more than just completing repetitive and highly detailed tasks accurately; it is the understanding that we...
InSightec is the world leader and innovator of MR-guided Focused Ultrasound (MRgFUS). The company`s non-invasive therapy platforms, Exablate and Exablate Neuro, are proven technology based on sound clinical evidence for treating essential tremor, painful bone metastases and uterine fibroids. The company is dedicated to improving patient lives by collaborating with physicians, medical institutions, academic researchers and regulatory bodies around the world.
Formulated Solutions innovates, formulates, creates and comarkets consumer brands. The company has assembled a broad and talented team of experts in manufacturing, production, laboratory, regulatory, distribution and marketing, possessing an unparalleled drive to deliver market-ready products of the highest integrity. In-house technologies in Aerosol, Biochemistry, Cosmetic, Pharmaceutical and Polymer Chemistry, coupled with innovative package design and strategic marketing services, provide the company`s clients with the fastest design-to-market solution in the world.
Sonic Packaging Industries is a Westwood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.